Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Today Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B.

7 Jan 2013

Crofelemer receives FDA approval for treatment of HIV associated diarrhea

Glenmark Pharmaceuticals Limited announced today that the US Food and Drug Administration has provided Marketing approval to its partner in US, Salix Pharmaceuticals Limited, for Crofelemer 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in patients with human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART).

2 Jan 2013

Early problems in processing knowledge-based information linked to Alzheimer's disease

People who study or treat Alzheimer's disease and its earliest clinical stage, mild cognitive impairment (MCI), have focused attention on the obvious short-term memory problems. But a new study suggests that people on the road to Alzheimer's may actually have problems early on in processing semantic or knowledge-based information, which could have much broader implications for how patients function in their lives.

29 Dec 2012

Cellular metabolism of immune cells protect against viral infections and tumours

New research demonstrates that the cellular metabolism of certain immune cells is closely linked to their function, which includes protecting against viral infections and the development of tumours.

25 Dec 2012

TNF inhibitor efficacy may depend on brain activity

How well a patient responds to tumor necrosis factor inhibitor therapy may depend on brain activity reflecting the individual’s perception of their rheumatoid arthritis, scientists believe.

24 Dec 2012

Viewpoints: Playing chicken on entitlements; 'Getting serious' about mental illness; Hospital labs devastated by Sandy

This is no time for a Grand Bargain, because the Republican Party, as now constituted, is just not an entity with which the president can make a serious deal. If we're going to get a grip on our nation's problems -; of which the budget deficit is a minor part -; the power of the G.O.P.'s extremists, and their willingness to hold the economy hostage if they don't get their way, needs to be broken. And somehow I don't think that's going to happen in the next few days (Paul Krugman, 12/20).

21 Dec 2012

Biotest receives FDA approval for BIVIGAM to treat primary humoral immunodeficiency

Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA).

20 Dec 2012

Positive top-line results from Idera’s IMO-3100 Phase 2a trial on plaque psoriasis

Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.

20 Dec 2012

Enlarged lymph nodes may warn of cancer

Enlarged lymph nodes are a marker for both occult cancer and a long-term risk for malignancy, confirms research published in the British Journal of Haematology.

19 Dec 2012

Amgen expected to enter a guilty plea to unspecified charges

The biotech giant is expected to plead guilty in a New York federal court criminal case. Some reports suggest the charges relate to "misbranding" -- which refers to the promotion of drugs for uses that have not gained the Food and Drug Administration's approval.

19 Dec 2012

Australian scientists receive grants for research on cancer, malaria and rheumatoid arthritis

Scientists at the Walter and Eliza Hall Institute in Melbourne, Australia, have received more than $16 million in Australian Government funding to pursue research into cancer, malaria, rheumatoid arthritis and the immune system, it was announced today.

19 Dec 2012

University of Maryland, Baltimore hosts first national conference on oral and systemic health

By hosting the first national conference on oral and systemic health in Baltimore on Dec. 10, the University of Maryland, Baltimore (UMB) took another major step toward true interprofessional health care education, says Jay A. Perman, MD, president of the University.

19 Dec 2012

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

Osteoporosis screening: an interview with Professor Cyrus Cooper

Osteoporosis is defined as a reduction in bone mass coupled with micro-architectural deterioration of bone tissue which predisposes to fractures. Osteoporosis manifests through an increased risk of fracture, and age-related fractures are a major public health problem.

17 Dec 2012

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration for the development of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).

17 Dec 2012

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

Amgen declares $0.47 per share dividend for first quarter 2013

Amgen announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Amgen signs definitive agreement to acquire deCODE Genetics

Amgen and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland.

10 Dec 2012

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Crofelemer receives FDA approval for treatment of HIV associated diarrhea

Early problems in processing knowledge-based information linked to Alzheimer's disease

Cellular metabolism of immune cells protect against viral infections and tumours

TNF inhibitor efficacy may depend on brain activity

Viewpoints: Playing chicken on entitlements; 'Getting serious' about mental illness; Hospital labs devastated by Sandy

Biotest receives FDA approval for BIVIGAM to treat primary humoral immunodeficiency

Positive top-line results from Idera’s IMO-3100 Phase 2a trial on plaque psoriasis

Enlarged lymph nodes may warn of cancer

Amgen expected to enter a guilty plea to unspecified charges

Australian scientists receive grants for research on cancer, malaria and rheumatoid arthritis

University of Maryland, Baltimore hosts first national conference on oral and systemic health

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Osteoporosis screening: an interview with Professor Cyrus Cooper

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

Amgen declares $0.47 per share dividend for first quarter 2013

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Amgen signs definitive agreement to acquire deCODE Genetics

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in